BR112012029994A2 - composto heterocíclicos como inibidores de janus quinase - Google Patents

composto heterocíclicos como inibidores de janus quinase

Info

Publication number
BR112012029994A2
BR112012029994A2 BR112012029994A BR112012029994A BR112012029994A2 BR 112012029994 A2 BR112012029994 A2 BR 112012029994A2 BR 112012029994 A BR112012029994 A BR 112012029994A BR 112012029994 A BR112012029994 A BR 112012029994A BR 112012029994 A2 BR112012029994 A2 BR 112012029994A2
Authority
BR
Brazil
Prior art keywords
formula
compounds
kinase inhibitors
janus kinase
heterocyclic compounds
Prior art date
Application number
BR112012029994A
Other languages
English (en)
Inventor
Wu Minwan
L Kotian Pravin
S Babu Yarlagada
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of BR112012029994A2 publication Critical patent/BR112012029994A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto heterocíclicos como inibidores de janus quinase. a invenção fornece compostos da fórmula i: ou um sal do mesmo como descrito aqui, a invenção também fornece composições farmacêuticas que compreendem um composto da fórmula i, processos para preparar compostos da fórmula i, intermediários úteis para preparar compostos da fórmula i e métodos terapêuticos para suprimir uma resposta imunológica ou tratar câncer ou uma malignidade hematológica usando do compostos da fórmula i.
BR112012029994A 2010-05-28 2011-05-27 composto heterocíclicos como inibidores de janus quinase BR112012029994A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34936410P 2010-05-28 2010-05-28
PCT/US2011/038387 WO2011150356A1 (en) 2010-05-28 2011-05-27 Heterocyclic compounds as janus kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112012029994A2 true BR112012029994A2 (pt) 2019-09-24

Family

ID=44210994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012029994A BR112012029994A2 (pt) 2010-05-28 2011-05-27 composto heterocíclicos como inibidores de janus quinase

Country Status (13)

Country Link
US (1) US20130071415A1 (pt)
EP (1) EP2576561A1 (pt)
JP (1) JP2013530951A (pt)
KR (1) KR20130083389A (pt)
CN (1) CN102971323A (pt)
AR (1) AR081428A1 (pt)
AU (1) AU2011258005A1 (pt)
BR (1) BR112012029994A2 (pt)
CA (1) CA2799926A1 (pt)
IL (1) IL223131A0 (pt)
MX (1) MX2012013824A (pt)
TW (1) TW201202246A (pt)
WO (1) WO2011150356A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242988B2 (en) 2012-10-17 2016-01-26 Merck Sharp & Dohme Corp. 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2909210A4 (en) 2012-10-17 2016-04-06 Merck Sharp & Dohme 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
CA2910759C (en) 2013-05-02 2018-01-16 Pfizer Inc. Imidazo-triazine derivatives as pde10 inhibitors
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
CN109232575B (zh) * 2017-07-10 2022-01-25 中国科学院上海药物研究所 吡咯[1,2-b]哒嗪类化合物或其可药用盐及它们的用途
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
MX2021011302A (es) 2019-03-19 2022-01-19 Boehringer Ingelheim Animal Health Usa Inc Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos.
CN114599366A (zh) 2019-09-19 2022-06-07 托特斯医药公司 治疗性缀合物
PE20231205A1 (es) 2020-05-29 2023-08-17 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos
WO2022028492A1 (en) * 2020-08-05 2022-02-10 Beigene, Ltd. Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors
WO2023046900A1 (en) 2021-09-23 2023-03-30 Katholieke Universiteit Leuven Ribonucleoside analogues against -sars-cov-2
AU2022377394A1 (en) 2021-11-01 2024-06-13 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260756A (en) * 1979-11-15 1981-04-07 American Cyanamid Company 6- And 8-heteroaryl-1,2,4-triazolo[4,3-b]pyridazines
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP3138117B2 (ja) 1993-06-11 2001-02-26 株式会社トクヤマ 新規化合物
JPH06345772A (ja) 1993-06-15 1994-12-20 Tokuyama Soda Co Ltd 新規化合物
JPH07285931A (ja) 1994-04-19 1995-10-31 Tokuyama Corp 新規化合物
JP4649046B2 (ja) * 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
EP1217001B1 (en) 1999-09-28 2005-12-07 Eisai Co., Ltd. Quinuclidine compounds and drugs containing the same as the active ingredient
GEP20063915B (en) * 2000-11-17 2006-09-11 Bristol Myers Squibb Co PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
ES2291729T7 (es) * 2003-01-09 2010-03-31 Astellas Pharma Inc. Derivados de pirrolopiridazina.
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
EP2324020A2 (en) * 2008-08-01 2011-05-25 Biocryst Pharmaceuticals, Inc. Piperidine derivatives as jak3 inhibitors
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CN102596961B (zh) * 2009-10-30 2015-12-02 詹森药业有限公司 咪唑并[1，2-b]哒嗪衍生物及其作为PDE10抑制剂的用途

Also Published As

Publication number Publication date
IL223131A0 (en) 2013-02-03
TW201202246A (en) 2012-01-16
MX2012013824A (es) 2013-03-12
AR081428A1 (es) 2012-08-29
EP2576561A1 (en) 2013-04-10
CN102971323A (zh) 2013-03-13
KR20130083389A (ko) 2013-07-22
WO2011150356A1 (en) 2011-12-01
JP2013530951A (ja) 2013-08-01
CA2799926A1 (en) 2011-12-01
AU2011258005A1 (en) 2013-01-17
US20130071415A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
BR112012029994A2 (pt) composto heterocíclicos como inibidores de janus quinase
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
BR112012008073A2 (pt) compostos heterocíclicos como inibidores de janus quinase
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX362550B (es) Inhibidores ciclicos de glutaminasa.
JO2998B1 (ar) مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
EP4257591A3 (en) Inhibitors of lysine specific demethylase-1
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
MX2011012037A (es) Compuestos de heteroarilo como inhibidores de pikk.
NZ708382A (en) Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents
MX2013012981A (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201300052A1 (ru) [1,8]нафтиридиновые производные
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
EA201291246A1 (ru) Конденсированные бициклические ингибиторы киназы
WO2011079230A3 (en) Heterocyclic compounds as janus kinase inhibitors
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
MY160392A (en) Triptolide prodrugs
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.